Real-life efficacy and safety of vildagliptin compared with sulfonylureas as add-on to metformin in patients with type 2 diabetes mellitus in Germany

Author： Göke R.   Gruenberger J. B.   Bader G.   Dworak M.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.30, Iss.5, 2014-05, pp. : 785-789

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Treatment adherence with vildagliptin compared to sulphonylurea as add-on to metformin in Muslim patients with type 2 diabetes mellitus fasting during Ramadan

By Hanif W.  

Current Medical Research and Opinion, Vol. 29, Iss. 7, 2013-07 ,pp. : 807-811

Informa Healthcare

Access to resources Recommend Favorite

Effectiveness of vildagliptin as add‐on to metformin monotherapy among uncontrolled type 2 diabetes mellitus patients in a real‐world setting

By  

JOURNAL OF DIABETES, Vol. 10, Iss. 1, 2018-01 ,pp. : 68-72

John Wiley & Sons Inc

Access to resources Recommend Favorite

Empagliflozin as add‐on to metformin in people with Type 2 diabetes

By  

DIABETIC MEDICINE, Vol. 32, Iss. 12, 2015-12 ,pp. : 1555-1567

John Wiley & Sons Inc

Access to resources Recommend Favorite

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 3, 2018-03 ,pp. : 530-540

John Wiley & Sons Inc

Access to resources Recommend Favorite